Enable Injections Secures $30M Investment from Sanofi for enFuse OBDS Development
January 6, 2026 did not show up with confetti. It showed up with intent. Enable Injections secured a $30M strategic investment from Sanofi, and it reads less like a transaction and more like a long-running conversation reaching its next verse. When the same global pharma partner leads a Series B in 2018, backs a $215M Series C in 2022, and then comes back again, that is not habit. That is alignment forged under pressure.
Enable Injections was built in Cincinnati by Michael D. Hooven, a founder who does not romanticize invention. More than 30 years in medical devices, 100+ issued and pending patents, and a track record that includes founding Enable Medical and scaling AtriCure into a public company. The thesis was simple and uncomfortable. Patients were losing hours of their lives to IV infusions because the system never bothered to ask if there was a better way.
The enFuse On-Body Delivery System answered that question with mechanics, not hype. Large volume biologics delivered subcutaneously in minutes, not hours. No batteries, no electronics, no theatrics. Just precision, comfort, and a design that respects existing drug containers so partners do not have to burn years on reformulation. Patients noticed. Adoption climbed fast after FDA approval for EMPAVELI in October 2023, with compliance hitting 97% and preference rates that left infusion pumps looking like relics.
Sanofi knows this platform well. The Sarclisa partnership has already moved through Phase 2 and Phase 3 programs, including IRAKLIA and IZALCO, showing a 99.9% successful delivery rate and dramatically fewer systemic infusion reactions versus IV. When data like that shows up, capital follows. This $30M is not dilution. It is reinforcement aimed directly at scale.
That scale now lives in Springdale, Ohio. A 90,000 sq ft Manufacturing Center of Excellence opened at the end of 2024, built around modular lines capable of producing 1.5M units annually. Robotic assembly, GMP clean rooms, and a supply chain designed for commercial reality, not lab optimism. This is manufacturing for companies that already know demand is real.
Matthew J. Huddleston operates at the crossroads as EVP, CTO, and CCO, where technology meets revenue without translation errors. That posture explains why Roche, Apellis, CSL Behring, Sobi, Serina Therapeutics, Incyte, and Sanofi all sit on the same partner list. Frictionless platforms attract serious adults with serious timelines.
Zoom out and the math gets louder. Subcutaneous biologics are growing fast, home administration keeps winning, and large volume delivery remains underserved. Enable Injections now sits there with FDA approval, global regulatory momentum, 7 major pharma partnerships, and $329M+ raised. This investment says something quietly disruptive. The future of biologics delivery is smaller, faster, and built around patients instead of chairs. The capital already knows where it is headed.